Abstract
Statin reduces cerebrovascular events independent of its cholesterol lowering effect. We hypothesized that statin inhibits early atherosclerotic change in common carotid artery (CCA), and investigated its effect on lectin-like oxidized-LDL receptor-1 (LOX-1) and monocyte chemoattractant protein-1 (MCP-1) expression, both of which are early atherosclerotic markers. Stroke-prone spontaneous hypertensive rats (SHR-SP) of 8 weeks old were orally treated with vehicle or simvastatin (20mg/kg) daily. After 4 weeks of simvastatin or vehicle treatment, or 2 weeks of vehicle and 2 weeks of simvastatin treatment, CCA was removed. LOX-1 and MCP-1 expression as well as macrophage infiltration were histologically investigated. Lipid deposition was also investigated by Sudan III staining. Simvastatin groups showed significantly smaller amount of lipid deposition and LOX-1 and MCP-1 expression, independent of serum lipid levels. Macrophage infiltration was also decreased. Reduction of cerebrovascular events by statins may be brought by the direct inhibition of atherosclerotic change.
Keywords: Atherosclerosis, carotid artery, hyperlipidemia, lectin-like oxidized-LDL receptor-1, lipid deposition, macrophage infiltration, monocyte chemoattractant protein-1, statin
Current Neurovascular Research
Title: Macrophage Infiltration, Lectin-Like Oxidized-LDL Receptor-1, and Monocyte Chemoattractant Protein-1 are reduced by Chronic HMG-CoA Reductase Inhibition
Volume: 4 Issue: 4
Author(s): Atsushi Tsuchiya, Shoko Nagotani, Takeshi Hayashi, Kentaro Deguchi, Yoshihide Sehara, Toru Yamashita, HanZhe Zhang, Violeta Lukic, Tatsushi Kamiya and Koji Abe
Affiliation:
Keywords: Atherosclerosis, carotid artery, hyperlipidemia, lectin-like oxidized-LDL receptor-1, lipid deposition, macrophage infiltration, monocyte chemoattractant protein-1, statin
Abstract: Statin reduces cerebrovascular events independent of its cholesterol lowering effect. We hypothesized that statin inhibits early atherosclerotic change in common carotid artery (CCA), and investigated its effect on lectin-like oxidized-LDL receptor-1 (LOX-1) and monocyte chemoattractant protein-1 (MCP-1) expression, both of which are early atherosclerotic markers. Stroke-prone spontaneous hypertensive rats (SHR-SP) of 8 weeks old were orally treated with vehicle or simvastatin (20mg/kg) daily. After 4 weeks of simvastatin or vehicle treatment, or 2 weeks of vehicle and 2 weeks of simvastatin treatment, CCA was removed. LOX-1 and MCP-1 expression as well as macrophage infiltration were histologically investigated. Lipid deposition was also investigated by Sudan III staining. Simvastatin groups showed significantly smaller amount of lipid deposition and LOX-1 and MCP-1 expression, independent of serum lipid levels. Macrophage infiltration was also decreased. Reduction of cerebrovascular events by statins may be brought by the direct inhibition of atherosclerotic change.
Export Options
About this article
Cite this article as:
Tsuchiya Atsushi, Nagotani Shoko, Hayashi Takeshi, Deguchi Kentaro, Sehara Yoshihide, Yamashita Toru, Zhang HanZhe, Lukic Violeta, Kamiya Tatsushi and Abe Koji, Macrophage Infiltration, Lectin-Like Oxidized-LDL Receptor-1, and Monocyte Chemoattractant Protein-1 are reduced by Chronic HMG-CoA Reductase Inhibition, Current Neurovascular Research 2007; 4 (4) . https://dx.doi.org/10.2174/156720207782446333
DOI https://dx.doi.org/10.2174/156720207782446333 |
Print ISSN 1567-2026 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5739 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Detrimental Effects of Hyperglycemia in Acute Coronary Syndromes: from Pathophysiological Mechanisms to Therapeutic Strategies
Mini-Reviews in Medicinal Chemistry Apoptosis in Atherosclerosis: A Mini-Review
Mini-Reviews in Medicinal Chemistry Aetiology, Diagnosis and Treatment of Hydrops Foetalis
Current Pediatric Reviews Acknowledgements to Reviewers
Current Hypertension Reviews Patent Selections:
Recent Patents on Cardiovascular Drug Discovery Oxaliplapin and Capecitabine (XELOX) Based Chemotherapy in the Treatment of Metastatic Colorectal Cancer: The Right Choice in Elderly Patients
Anti-Cancer Agents in Medicinal Chemistry Dissections of the Thoracic Aorta and Evolving Endovascular Strategies
Current Hypertension Reviews Heterocyclic Chalcone Analogues as Potential Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Investigation of Drug Interaction Potentials and Binding Modes on Direct Renin Inhibitors: A Computational Modeling Studies
Letters in Drug Design & Discovery Preface [Hot topic: Insulin Resistance and Impaired Coronary Endothelial Function (Guest Editor: Teruo Inoue)]
Current Drug Targets - Cardiovascular & Hematological Disorders A Systematic Review of Grand Multiparity
Current Women`s Health Reviews Cardiac Consequences of Anti-Inflammatory Drugs in Experimental Models
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Apoptogenic Signal Transduction in Arteriosclerosis-Associated Cells – Opportunities for Future Therapy?
Vascular Disease Prevention (Discontinued) Meet Our Editor
Current Respiratory Medicine Reviews Adenosine Receptor Ligands in Clinical Trials
Current Topics in Medicinal Chemistry The Antagonists of Endothelin Receptors: Results and Perspectives
Current Pharmaceutical Analysis Do Histamine receptor 3 antagonists have a place in the therapy for schizophrenia?
Current Pharmaceutical Design Latest Advances in Breast Sonography
Recent Patents on Medical Imaging Leptin Plasma Levels in the General Population: Influence of Age, Gender, Body Weight and Medical History
Protein & Peptide Letters Novel Oral Anticoagulants in the Treatment of Acute Coronary Syndromes: Is there any Room for New Anticoagulants?
Current Clinical Pharmacology